Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Yvette Robbins, Jay Friedman, Paul E Clavijo, Cem Sievers, Ke Bai, Renee N Donahue, Jeffrey Schlom, Andrew Sinkoe, Christian S Hinrichs, Clint Allen, Houssein Abdul Sater, James L Gulley, Scott Norberg, Yvette Robbins, Jay Friedman, Paul E Clavijo, Cem Sievers, Ke Bai, Renee N Donahue, Jeffrey Schlom, Andrew Sinkoe, Christian S Hinrichs, Clint Allen, Houssein Abdul Sater, James L Gulley, Scott Norberg
Abstract
Background: Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV) driven neoplastic disorder of the upper aerodigestive tract that causes significant morbidity and can lead to fatal airway obstruction. Prior clinical study demonstrated clinical benefit with the programmed death-ligand 1 (PD-L1) monoclonal antibody avelumab. Bintrafusp alpha is a bifunctional inhibitor of PD-L1 and transforming growth factor-beta (TGF-b) that has shown clinical activity in several cancer types.
Methods: We conducted a phase II clinical trial evaluating bintrafusp alpha in adults with RRP. Papilloma samples before and after treatment with bintrafusp alpha were assessed for correlates of response with multiplex immunofluorescence as well as immunological and genomic analyses. Post hoc analyses of papilloma samples before and after treatment with avelumab were assessed for comparison.
Results: Dual PD-L1/TGF-b inhibition failed to abrogate papilloma growth in most subjects and increased the frequency of clinically indicated interventions after treatment in four of eight subjects based on each subject's own historical control. TGF-b neutralization consistently decreased pSMAD3 and p21 and increased Ki67 expression within the basal layers of papillomas, indicating that TGF-b restrained proliferation. These alterations were not observed in papillomas treated with PD-L1 blockade alone. Dual PD-L1/TGF-b inhibition did not enhance anti-HPV immunity within papillomas beyond that observed with PD-L1 blockade. Genomic alterations in TGF-b superfamily genes were infrequent in papillomas and normal mucosa but present in a significant fraction of head and neck carcinomas.
Conclusions: Intact TGF-b signaling restrains proliferation within papillomas, and the use of clinical agents that abrogate this pathway should be avoided in patients with RRP.
Trial registration numbers: NCT03707587 and NCT02859454.
Keywords: head and neck neoplasms; immunohistochemistry; immunotherapy; investigational; therapies; tumor microenvironment.
Conflict of interest statement
Competing interests: None.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Zhang Y, Alexander PB, Wang X-F. TGF-β Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb Perspect Biol 2017;9:a022145. 10.1101/cshperspect.a022145
- Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity 2019;50:924–40. 10.1016/j.immuni.2019.03.024
- Wakefield LM, Stuelten C. Keeping order in the neighborhood: new roles for TGFbeta in maintaining epithelial homeostasis. Cancer Cell 2007;12:293–5. 10.1016/j.ccr.2007.10.002
- Mariathasan S, Turley SJ, Nickles D, et al. . Tgfβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018;554:544–8. 10.1038/nature25501
- Tauriello DVF, Palomo-Ponce S, Stork D, et al. . Tgfβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018;554:538–43. 10.1038/nature25492
- Thomas DA, Massagué J. Tgf-Beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369–80. 10.1016/j.ccr.2005.10.012
- Viel S, Marçais A, Guimaraes FS-F, et al. . TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal 2016;9:ra19. 10.1126/scisignal.aad1884
- Zhang J, Tian X-J, Zhang H, et al. . TGF-β-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci Signal 2014;7:ra91. 10.1126/scisignal.2005304
- Canè S, Van Snick J, Uyttenhove C, et al. . Tgfβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism. J Immunother Cancer 2021;9:e001798. 10.1136/jitc-2020-001798
- Holmgaard RB, Schaer DA, Li Y, et al. . Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer 2018;6:47. 10.1186/s40425-018-0356-4
- Lan Y, Zhang D, Xu C, et al. . Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med 2018;10. 10.1126/scitranslmed.aan5488. [Epub ahead of print: 17 01 2018].
- Allen CT, Lee S, Norberg SM, et al. . Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. J Immunother Cancer 2019;7:119. 10.1186/s40425-019-0603-3
- Hester RP, Derkay CS, Burke BL, et al. . Reliability of a staging assessment system for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2003;67:505–9. 10.1016/S0165-5876(03)00007-7
- Bankhead P, Loughrey MB, Fernández JA, et al. . QuPath: open source software for digital pathology image analysis. Sci Rep 2017;7:16878. 10.1038/s41598-017-17204-5
- Cancer Genome Atlas Network . Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576–82. 10.1038/nature14129
- Li H, Handsaker B, Wysoker A. Genome project data processing S: the sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078–9.
- McKenna A, Hanna M, Banks E, et al. . The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297–303. 10.1101/gr.107524.110
- Wang M, Luo W, Jones K, et al. . SomaticCombiner: improving the performance of somatic variant calling based on evaluation tests and a consensus approach. Sci Rep 2020;10:12898. 10.1038/s41598-020-69772-8
- Wilm A, Aw PPK, Bertrand D, et al. . LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res 2012;40:11189–201. 10.1093/nar/gks918
- Fan Y, Xi L, Hughes DST, et al. . Muse: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biol 2016;17:178. 10.1186/s13059-016-1029-6
- Kim S, Scheffler K, Halpern AL, et al. . Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods 2018;15:591–4. 10.1038/s41592-018-0051-x
- Chen X, Schulz-Trieglaff O, Shaw R, et al. . Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 2016;32:1220–2. 10.1093/bioinformatics/btv710
- McLaren W, Gil L, Hunt SE, et al. . The Ensembl variant effect predictor. Genome Biol 2016;17:122. 10.1186/s13059-016-0974-4
- Mayakonda A, Lin D-C, Assenov Y, et al. . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 2018;28:1747–56. 10.1101/gr.239244.118
- Flensburg C, Sargeant T, Oshlack A, et al. . SuperFreq: integrated mutation detection and clonal tracking in cancer. PLoS Comput Biol 2020;16:e1007603. 10.1371/journal.pcbi.1007603
- Strauss J, Gatti-Mays ME, Cho BC, et al. . Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer 2020;8:e001395. 10.1136/jitc-2020-001395
- Korkut A, Zaidi S, Kanchi RS, et al. . A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-β superfamily. Cell Syst 2018;7:e427:422–37. 10.1016/j.cels.2018.08.010
- Yang Y, Yang HH, Tang B, et al. . The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ. Clin Cancer Res 2020;26:643–56. 10.1158/1078-0432.CCR-19-2370
- Yeh H-W, Lee S-S, Chang C-Y, et al. . A new switch for TGFβ in cancer. Cancer Res 2019;79:3797–805. 10.1158/0008-5472.CAN-18-2019
- Cohen J, Chen Z, Lu S-L, et al. . Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Res 2009;69:3415–24. 10.1158/0008-5472.CAN-08-3704
- Levovitz C, Chen D, Ivansson E, et al. . Tgfβ receptor 1: an immune susceptibility gene in HPV-associated cancer. Cancer Res 2014;74:6833–44. 10.1158/0008-5472.CAN-14-0602-T
- Cho BC, Daste A, Ravaud A, et al. . Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer 2020;8:e000664. 10.1136/jitc-2020-000664
- Hatam LJ, Devoti JA, Rosenthal DW, et al. . Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression. Clin Cancer Res 2012;18:1925–35. 10.1158/1078-0432.CCR-11-2941
- Liu T, Zhou L, Li D, et al. . Cancer-Associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol 2019;7:60. 10.3389/fcell.2019.00060
- Lacouture ME, Morris JC, Lawrence DP, et al. . Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol Immunother 2015;64:437–46. 10.1007/s00262-015-1653-0
- Goudie DR, D'Alessandro M, Merriman B, et al. . Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet 2011;43:365–9. 10.1038/ng.780
Source: PubMed